Appeal No. 2006-3200 Page 2
Application No. 10/196,428
wherein R1 represents an organic group, X represents -CH2CH2- or
-CH=CH-, and R2 represents a hydrogen atom or an alkyl group, or a
lactone derivative thereof, or a salt thereof, as an active ingredient,
wherein the organic group is a 5 or 6 membered cyclic structure
containing 0 to 2 heteroatoms selected from the group consisting of N, O,
and S or a condensed ring thereof,
with the proviso that the compound of formula (1) is not
atorvastatin; and
wherein said subject in need thereof suffers from rheumatoid
arthritis.
The references relied upon by the Examiner are:
Bokoch 5,244,916 Sep. 14, 1993
Partridge 6,403,637 Jun. 11, 2002
Chao WO 01/22962 Apr. 5, 2001
Luchetti et al. (Luchetti), “Expression and production of the long pentraxin PTX3
in rheumatoid arthritis (RA), Clin Exp. Immunol., Vol. 119, pp. 196-202 (2000).
GROUND OF REJECTION
Claims 1-4 and 16-22 stand rejected under 35 U.S.C. § 103(a) as being
unpatentable over the combination of Chao, Bokoch, Partridge and Luchetti.
We affirm.
CLAIM GROUPING
Appellants do not separately group or argue the claims before us on
appeal. Accordingly the claims stand or fall together. Since all claims stand or
fall together, we limit our discussion to representative independent claim 1. 37
C.F.R. § 1.192(c)(7) (rev. 2, May 2004). Claims 2-4 and 16-22 will stand or fall
together with claim 1. In re Young, 927 F.2d 588, 590, 18 USPQ2d 1089, 1091
(Fed. Cir. 1991).
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: September 9, 2013